Dow Up1.06% Nasdaq Up1.74%

Cleveland BioLabs, Inc. (CBLI)

-NasdaqCM
0.41 Up 0.03(9.04%) 12:07PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Cleveland BioLabs, Inc.
73 High Street
Buffalo, NY 14203
United States - Map
Phone: 716-849-6810
Fax: 716-849-6820
Website: http://www.cbiolabs.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:44

Business Summary 

Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with significant medical need. Its lead drug candidates include Entolimod, which is being developed as radiation countermeasure for prevention of death from acute radiation syndrome and as an oncology drug; and CBL0137, which is in two multi-center, single agent, dose escalation Phase I studies in subjects with advanced solid tumors. The company’s clinical stage product candidates comprise CBL0102, which has completed Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and Entolimod, which is in Phase I clinical trials for open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity in advanced cancer patients. Its preclinical stage product candidates include CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin. The company has license agreements and collaborations with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, and Buffalo BioLabs. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Cleveland BioLabs, Inc.

Key Executives 
 PayExercised
Dr. Yakov N. Kogan Ph.D., M.B.A., 41
Co-Founder, Chief Exec. Officer and Director
417.00K0.00
Dr. Michael Fonstein Ph.D., 55
Co-Founder
520.00K0.00
Dr. Andrei V. Gudkov Ph.D., D.Sci., 58
Co-Founder, Chief Scientific Officer and Director
215.00K0.00
Mr. C. Neil Lyons CPA, 57
Chief Financial Officer and Exec. VP
265.00K0.00
Dr. George R. Stark Ph.D., FRS,
Co-Founder, Consultant and Advisor
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders